Se­lec­ta lets go 25% of work­force, paus­es PhI/II gene ther­a­py tri­al

Se­lec­ta Bio­sciences, which is de­vel­op­ing im­munother­a­pies and gene ther­a­pies, is cut­ting its work­force by 25% and paus­ing de­vel­op­ment of its whol­ly-owned gene ther­a­py pro­grams.

The com­pa­ny an­nounced the work­force re­duc­tion and a clin­i­cal tri­al pause on Thurs­day dur­ing its first-quar­ter earn­ings re­port, say­ing the ac­tions would ex­tend the biotech’s cash run­way in­to the first half of 2025.

It now plans to fo­cus on the li­cens­ing deal it struck with So­bi in 2020 for its gout can­di­date, and ad­vanc­ing its pre­ci­sion im­mune tol­er­ance plat­form.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER